Valuating News Today

EQSAdhoc EVN AG Key word InvestmentDisposal EVN AG EVN terminates the structured bidder process for a full sale of WTE and is evaluating further strategic options 04Apr2024 2312 CETCEST Disclosure of

Polestar Automotive Holding UK PLC (Nasdaq: PSNY), the Swedish electric performance car brand, welcomes Geely Sweden Holding as a potential direct new shareholder. Volvo Cars is evaluating a potential adjustment to its shareholding in Polestar including a distribution of shares to its shareholders, with Geely Sweden Holding being the primary recipient. Volvo Cars will remain a strategic partner in areas across R&D, manufacturing, after sales and commercial. Polestar has made significant p...

Amdocs (NASDAQ: DOX), a leading provider of software and services to communications and media companies, today announced that it has been recognized for its commitment to sustainability and corporate responsibility, earning a place on the prestigious S&P Dow Jones Sustainability Index (DJSI) for North America for the fifth consecutive year. The Dow Jones Sustainability Indices are widely regarded as one of the most important global indicators of sustainability leadership, evaluating publi...

Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients

On June 8, 2023, International Game Technology PLC announced that its board of directors is evaluating potential strategic alternatives for the companys Global Gaming and PlayDigital segments in... | June 9, 2023

RAINBOW study design enables rapid advancement into the company's planned Phase 3 efficacy trial Azafaros B.V. today announced that the first patient has been enrolled into its Phase 2 RAINBOW

Bellerophon Therapeutics, Inc. announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INOpulse® for the treatment of fibrotic Interstitial... | June 6, 2023

Oral presentation highlights first data from the GDFATHER-2a trial demonstrating lasting and confirmed responses (as per RECIST criteria) following treatment with visugromab and the anti-PD-1 inhibitor

- Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable

- Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p - 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of - New Data Demonstrate